BMRN Stock Overview
Engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BMRN passed our risk checks.
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$62.56 |
| 52 Week High | US$99.56 |
| 52 Week Low | US$61.15 |
| Beta | 0.31 |
| 11 Month Change | -10.98% |
| 3 Month Change | -30.50% |
| 1 Year Change | -29.25% |
| 33 Year Change | -30.16% |
| 5 Year Change | -22.17% |
| Change since IPO | 376.65% |
Recent News & Updates
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21Recent updates
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Shareholder Returns
| BMRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | -6.5% | -1.0% |
| 1Y | -29.2% | 14.6% | 30.3% |
Return vs Industry: BMRN underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: BMRN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BMRN volatility | |
|---|---|
| BMRN Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BMRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMRN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,401 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| BMRN fundamental statistics | |
|---|---|
| Market cap | US$11.81b |
| Earnings (TTM) | US$322.29m |
| Revenue (TTM) | US$2.75b |
37.0x
P/E Ratio4.3x
P/S RatioIs BMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMRN income statement (TTM) | |
|---|---|
| Revenue | US$2.75b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$1.44b |
| Other Expenses | US$1.12b |
| Earnings | US$322.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 52.35% |
| Net Profit Margin | 11.71% |
| Debt/Equity Ratio | 11.0% |
How did BMRN perform over the long term?
See historical performance and comparison